Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Chanan-Khan A, et al. Among authors: phelps c. Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655421 Clinical Trial.
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A. Fraser G, et al. Among authors: phelps c. Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12. Leukemia. 2019. PMID: 30315239 Free PMC article. Clinical Trial.
Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Child F, et al. Among authors: phelps c. Br J Dermatol. 2016 Jul;175(1):80-8. doi: 10.1111/bjd.14427. Epub 2016 Jun 2. Br J Dermatol. 2016. PMID: 26836950 Clinical Trial.
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
Zinzani PL, Wang H, Feng J, Kim TM, Tao R, Zhang H, Fogliatto L, Maluquer Artigal C, Özcan M, Yanez E, Kim WS, Kirtbaya D, Kriachok I, Maciel F, Xue H, Bouabdallah K, Phelps C, Chaturvedi S, Weispfenning A, Morcos PN, Odongo F, Buvaylo V, Childs BH, Dreyling M, Matasar M, Ghione P. Zinzani PL, et al. Among authors: phelps c. Blood Adv. 2024 Sep 24;8(18):4866-4876. doi: 10.1182/bloodadvances.2024013236. Blood Adv. 2024. PMID: 39058951 Free PMC article. Clinical Trial.
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TR, de Bono JS, Banerji U. Venugopal B, et al. Among authors: phelps c. Clin Cancer Res. 2013 Aug 1;19(15):4262-72. doi: 10.1158/1078-0432.CCR-13-0312. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741066 Clinical Trial.
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP, Staddon A, Herremans C, Keung C, Bernard A, Phelps C, Khokhar NZ, Knoblauch R, Parekh TV, Dirix L, Sharma S. Machiels JP, et al. Among authors: phelps c. Cancer Chemother Pharmacol. 2014 Oct;74(4):729-37. doi: 10.1007/s00280-014-2554-1. Epub 2014 Aug 7. Cancer Chemother Pharmacol. 2014. PMID: 25100135 Clinical Trial.
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.
Shafrin J, Kim J, Cohen JT, Garrison LP, Goldman DA, Doshi JA, Krieger J, Lakdawalla DN, Neumann PJ, Phelps CE, Whittington MD, Willke R. Shafrin J, et al. Among authors: phelps ce. Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1. Forum Health Econ Policy. 2024. PMID: 39512185 Free PMC article.
Reply to Arun Joshi, Lazaros Tzelves, Zafer Tandogdu, Patrick Juliebø-Jones, and Bhaskar Somani's Letter to the Editor re: Christian Moro, Charlotte Phelps, Vineesha Veer, et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.07.002.
Moro C, Phelps C, Veer V, Jones M, Glasziou P, Clark J, Tikkinen KAO, Scott AM. Moro C, et al. Among authors: phelps c. Eur Urol Focus. 2024 Oct 3:S2405-4569(24)00182-2. doi: 10.1016/j.euf.2024.09.014. Online ahead of print. Eur Urol Focus. 2024. PMID: 39366884 No abstract available.
618 results